Cargando…
Single venom-based immunotherapy effectively protects patients with double positive tests to honey bee and Vespula venom
BACKGROUND: Referring to individuals with reactivity to honey bee and Vespula venom in diagnostic tests, the umbrella terms “double sensitization” or “double positivity” cover patients with true clinical double allergy and those allergic to a single venom with asymptomatic sensitization to the other...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3846485/ https://www.ncbi.nlm.nih.gov/pubmed/24004607 http://dx.doi.org/10.1186/1710-1492-9-33 |
_version_ | 1782293435616591872 |
---|---|
author | Stoevesandt, Johanna Hofmann, Bernd Hain, Johannes Kerstan, Andreas Trautmann, Axel |
author_facet | Stoevesandt, Johanna Hofmann, Bernd Hain, Johannes Kerstan, Andreas Trautmann, Axel |
author_sort | Stoevesandt, Johanna |
collection | PubMed |
description | BACKGROUND: Referring to individuals with reactivity to honey bee and Vespula venom in diagnostic tests, the umbrella terms “double sensitization” or “double positivity” cover patients with true clinical double allergy and those allergic to a single venom with asymptomatic sensitization to the other. There is no international consensus on whether immunotherapy regimens should generally include both venoms in double sensitized patients. OBJECTIVE: We investigated the long-term outcome of single venom-based immunotherapy with regard to potential risk factors for treatment failure and specifically compared the risk of relapse in mono sensitized and double sensitized patients. METHODS: Re-sting data were obtained from 635 patients who had completed at least 3 years of immunotherapy between 1988 and 2008. The adequate venom for immunotherapy was selected using an algorithm based on clinical details and the results of diagnostic tests. RESULTS: Of 635 patients, 351 (55.3%) were double sensitized to both venoms. The overall re-exposure rate to Hymenoptera stings during and after immunotherapy was 62.4%; the relapse rate was 7.1% (6.0% in mono sensitized, 7.8% in double sensitized patients). Recurring anaphylaxis was statistically less severe than the index sting reaction (P = 0.004). Double sensitization was not significantly related to relapsing anaphylaxis (P = 0.56), but there was a tendency towards an increased risk of relapse in a subgroup of patients with equal reactivity to both venoms in diagnostic tests (P = 0.15). CONCLUSIONS: Single venom-based immunotherapy over 3 to 5 years effectively and long-lastingly protects the vast majority of both mono sensitized and double sensitized Hymenoptera venom allergic patients. Double venom immunotherapy is indicated in clinically double allergic patients reporting systemic reactions to stings of both Hymenoptera and in those with equal reactivity to both venoms in diagnostic tests who have not reliably identified the culprit stinging insect. |
format | Online Article Text |
id | pubmed-3846485 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-38464852013-12-03 Single venom-based immunotherapy effectively protects patients with double positive tests to honey bee and Vespula venom Stoevesandt, Johanna Hofmann, Bernd Hain, Johannes Kerstan, Andreas Trautmann, Axel Allergy Asthma Clin Immunol Research BACKGROUND: Referring to individuals with reactivity to honey bee and Vespula venom in diagnostic tests, the umbrella terms “double sensitization” or “double positivity” cover patients with true clinical double allergy and those allergic to a single venom with asymptomatic sensitization to the other. There is no international consensus on whether immunotherapy regimens should generally include both venoms in double sensitized patients. OBJECTIVE: We investigated the long-term outcome of single venom-based immunotherapy with regard to potential risk factors for treatment failure and specifically compared the risk of relapse in mono sensitized and double sensitized patients. METHODS: Re-sting data were obtained from 635 patients who had completed at least 3 years of immunotherapy between 1988 and 2008. The adequate venom for immunotherapy was selected using an algorithm based on clinical details and the results of diagnostic tests. RESULTS: Of 635 patients, 351 (55.3%) were double sensitized to both venoms. The overall re-exposure rate to Hymenoptera stings during and after immunotherapy was 62.4%; the relapse rate was 7.1% (6.0% in mono sensitized, 7.8% in double sensitized patients). Recurring anaphylaxis was statistically less severe than the index sting reaction (P = 0.004). Double sensitization was not significantly related to relapsing anaphylaxis (P = 0.56), but there was a tendency towards an increased risk of relapse in a subgroup of patients with equal reactivity to both venoms in diagnostic tests (P = 0.15). CONCLUSIONS: Single venom-based immunotherapy over 3 to 5 years effectively and long-lastingly protects the vast majority of both mono sensitized and double sensitized Hymenoptera venom allergic patients. Double venom immunotherapy is indicated in clinically double allergic patients reporting systemic reactions to stings of both Hymenoptera and in those with equal reactivity to both venoms in diagnostic tests who have not reliably identified the culprit stinging insect. BioMed Central 2013-09-02 /pmc/articles/PMC3846485/ /pubmed/24004607 http://dx.doi.org/10.1186/1710-1492-9-33 Text en Copyright © 2013 Stoevesandt et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Stoevesandt, Johanna Hofmann, Bernd Hain, Johannes Kerstan, Andreas Trautmann, Axel Single venom-based immunotherapy effectively protects patients with double positive tests to honey bee and Vespula venom |
title | Single venom-based immunotherapy effectively protects patients with double positive tests to honey bee and Vespula venom |
title_full | Single venom-based immunotherapy effectively protects patients with double positive tests to honey bee and Vespula venom |
title_fullStr | Single venom-based immunotherapy effectively protects patients with double positive tests to honey bee and Vespula venom |
title_full_unstemmed | Single venom-based immunotherapy effectively protects patients with double positive tests to honey bee and Vespula venom |
title_short | Single venom-based immunotherapy effectively protects patients with double positive tests to honey bee and Vespula venom |
title_sort | single venom-based immunotherapy effectively protects patients with double positive tests to honey bee and vespula venom |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3846485/ https://www.ncbi.nlm.nih.gov/pubmed/24004607 http://dx.doi.org/10.1186/1710-1492-9-33 |
work_keys_str_mv | AT stoevesandtjohanna singlevenombasedimmunotherapyeffectivelyprotectspatientswithdoublepositiveteststohoneybeeandvespulavenom AT hofmannbernd singlevenombasedimmunotherapyeffectivelyprotectspatientswithdoublepositiveteststohoneybeeandvespulavenom AT hainjohannes singlevenombasedimmunotherapyeffectivelyprotectspatientswithdoublepositiveteststohoneybeeandvespulavenom AT kerstanandreas singlevenombasedimmunotherapyeffectivelyprotectspatientswithdoublepositiveteststohoneybeeandvespulavenom AT trautmannaxel singlevenombasedimmunotherapyeffectivelyprotectspatientswithdoublepositiveteststohoneybeeandvespulavenom |